- 2017 UPDATE OF THE ANTITRUST GUIDELINES FOR THE LICENSING OF INTELLECTUAL PROPERTY
- STANDARD SETTING AND COMPETITION November 8, 2012
- COMPETITION, INNOVATION AND INTELLECTUAL PROPERTY, April 26, 2012
- CHAPTER 6 : COMPETITIVE ISSUES REGARDING PRACTICES THAT EXTEND THE MARKET POWER CONFERRED BY A PATENT BEYOND ITS STATUTORY TERM
- Antitrust Division Manual, revised August 2017
- Advice of Attorney General with respect to antitrust law 40 USC §559 Note federal government owned patents are specially included in this obligation.
Some CPTech and KEI blogs and cases:
1996: Consumer Project asks the US Department of Justice to investigate West Publishing’s anticompetitive practices in legal publishing.
1996: Consumer Project and others oppose Thompson acquisition of West Publishing, and successfully seek acquisition of compulsory license on copyright claims to pagination of US court opinions.
1996: Letter to the U.S. Federal Trade Commission and the U.S. Department of Justice, expressing opposition to Boeing McDonnell Douglas Merger, by Ralph Nader, Center for Study of Responsive Law and Essential Information. December 23, 1996.
1997: Consumer Project on Technology successfully opposes merger between Staples and Office Depot.
1997: Consumer Project on Technology and others successively ask the US Department of Justice to bring antitrust case against Microsoft over it’s efforts to favor its Internet Explorer browser.
2000: James Love, Antitrust Considerations and the Petroleum Industry, Center for Study of Responsive Law. Prepared Statement for hearing on: Solutions to Competitive Problems in the Oil Industry, Committee on the Judiciary, House of Representatives Congress of the United States, March 29. A key and still relevant point raised in this testimony:
The current Department of Justice and Federal Trade Commission horizontal merger guidelines focus on market share metrics that understate concentration, by failing to address the degree and importance of joint ventures and other collaborations.
2003: CPTech’s 2003 reports for the RSA Competition Commission, in Hazel Tau et al.v GSK, Boehringer, et al. CPTech was the consultant to the Competition Commission staff that evaluated the Tau/TAC complaint, and investigated additional competition issues. GSK and Behringer were found to have violated RSA competition laws on three counts, including excessive pricing, refusal to license and blocking access to an essential facility. The excessive pricing case introduced a new paradigm for evaluating excessive prices on essential intellectual property goods (patented inventions on HIV drugs).
2004: Essential Inventions, Inc. letter to Susan Creighton of the Federal Trade Commission (FTC) Bureau of Competition, asking for investigation of Abbott Laboratories’ violation of antitrust laws. Abbott had raised the price of ritonavir in the United States by 400 percent, but only applied the price increase when the product was not co-formulated with Abbott’s fixed dose combination product Kalatera.
This is a “restraint of trade for which its patents afford no immunity from the anti-trust laws.” International Salt v. United States, 332 U.S. 392, 395-96 (1947).
2004: Essential Invention’s Norvir/ritonavir and Xalatan/latanoprost march-in cases, on grounds that prices in United States are not reasonable.
Ticketmaster/Live Nation merger
- 2009: Ticketmaster merger threatens consumer interest – Public interest and consumer groups ask DOJ to block merger
- 2009: Meeting at DOJ on the Ticketmaster /Live Nation merger
- 2009: Senate holds hearings on Ticketmaster/Live Nation merger
- 2009: Letter on Ticketmaster/Live Nation Merger: Ask your member of Congress to sign Pascrell letter to DOJ
- 2009: Timeline: Some important dates for MySQL and the proposed Oracle/Sun merger
- 2009: Eben Moglen’s neutron bomb therory of MySQL has some flaws
- 2009: 59 U.S. Senators write the EU to support Oracle acquisition of MYSQL
- 2009: Sun’s “Project Peter” – a plan to migrate Oracle users to MySQL
- 2009: KEI, Richard Stallman and ORG ask EC to block Oracle’s acquisition of MySQL
2012: KEI files affidavit in India compulsory licensing case involving Bayer patents on cancer drug Sorafenib (Nexavar) February 14. One issue is the question: is the price of Nexavar reasonably affordable in India?
- KEI asks FTC to block Celgene Acquisition of Juno Therapeutics, over BCMA-targeted CAR T treatment for Multiple Myeloma February 16, 2018.
- FTC approves Celgene acquisition of Juno without requiring divestitures/ February 21, 2018.
Review of the scope of 40 USC §559
KEI is asking the NIH to obtain DOJ approval of an exclusive license to Gilead for a CAR T technology, pursuant to 40 USC §559. The NIH says 40 USC §559 does not apply to the NIH use of exclusive licenses to patents.